Brief: Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject Data

Moleculin Biotech

07/05/2024 14:19

May 7 (Reuters) - Moleculin Biotech Inc  MBRX.O :
    * MOLECULIN REPORTS HIGHER AML COMPLETE REMISSION (CR) RATES
AND
SIGNIFICANT DURABILITY WITH ADDITIONAL INTERIM SUBJECT DATA
    * MOLECULIN BIOTECH: ANNAMYCIN IN COMBINATION WITH
CYTARABINE
(ANNARAC) ACHIEVES CRC RATE OF 62% (54% CR) IN 1(ST) AND 2(ND)
LINE AML SUBJECTS (N=13)

Source text for Eikon:  ID:nPn3Q7Cwra 
Further company coverage:  MBRX.O 

 ((Reuters.Briefs@thomsonreuters.com;))